Analysis of the short-term efficacy and side effects of concurrent chemoradiotherapy combined with nimotuzumab in patients with locally advanced nasopharyngeal carcinoma
Objective Nasopharyngeal carcinoma has unique anatomical and biological characteristics,and radiotherapy or concurrent chemoradiotherapy is an effective treatment mode.However,many patients with locally advanced nasopha-ryngeal carcinoma still experience local recurrence or distant metastasis.Therefore,targeted therapy provides an addition-al option for nasopharyngeal carcinoma patients.This article aims to evaluate the short-term efficacy and toxicity of con-current chemoradiotherapy combined with nimotuzumab in the treatment of locally advanced nasopharyngeal carcinoma pa-tients,and further analyze the impact of intensity-modulated radiation therapy(IMRT)and helical tomotherapy(TOMO)on patiens'side effects.Methods A retrospective analysis was conducted on the clinical data of 88 patients with locally advanced nasopharyngeal carcinoma admitted to the Radiotherapy Department of the First Affiliated Hospital of Bengbu Medical University from December 2020 to June 2023.The treatment group consisted of 44 patients who received concur-rent chemoradiotherapy with nimotuzumab targeted therapy,while the control group consisted of 44 patients who only re-ceived concurrent chemoradiotherapy.The short-term treatment efficacy,toxic side effects,and the impact of different ra-diotherapy methods on side effects were compared and analyzed.Results In the treatment group,the overall response rate(ORR)for the nasopharyngeal region and cervical lymph nodes were 97.8％(43/44)and 93.2％(41/44)respec-tively,while in the control group,the ORR were 81.8％(36/44)and 81.8％(36/44)respectively.The incidence of mucositis was higher in the treatment group compared to the control group:84.1％(37/44)compared to 63.6％(28/44),P＜0.05.Further analysis showed that the incidence of mucositis was lower in patients receiving TOMO in both the treatment and control groups than in the IMRT,but the difference was not statistically significant(P＞0.05).Conclusion For patients with locally advanced nasopharyngeal carcinoma,concurrent chemoradiotherapy with nimotuzumab provides better short-term efficacy,while patients receiving TOMO have a decreasing trend in mucosal reactions.
维普
万方数据
